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as evidenced by upregulation of the pre-frontal limbic regions in the
hand OA group. Development of future therapies could be targeted at
modulating activation of central pain processing centres in OA to
improve pain management in patients.
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RACIAL DIFFERENCES IN PAIN REPORTING IN SUBJECTS WITH OR AT
RISK FOR SYMPTOMATIC RADIOGRAPHIC KNEE OSTEOARTHRITIS:
DATA FROM THE OSTEOARTHRITIS INITIATIVE
P. Luneburg, L. Yerges-Armstrong, B. Mitchell, M.C. Hochberg. Univ. of
Maryland, Baltimore, MD, USA
Purpose: African Americans have a higher prevalence of both radiographic
and symptomatic radiographic knee OA (KOA) than Caucasian Americans.
While the reasons for this disparity are poorly understood, differences in
risk factor patterns, coping mechanisms, and/or pathoanatomic character-
istics have been suggested. Less is known, however, about differences in
clinical examination features of the knee between the two groups and
whether such differences may explain the greater frequency of pain and
higher pain reporting in African Americans with knee OA.
Methods: Racial differences in pain reporting and severity as well as
ﬁndings on physical examination of the knees were assessed using
baseline data from subjects enrolled in the Osteoarthritis Initiative
(OAI). The OAI is a multicenter, longitudinal observational study initi-
ated in 2004 to examine biomarkers and risk factors for clinically
signiﬁcant knee OA. This analysis included 372 African Americans and
974 Caucasians with symptomatic radiographic KOA in at least one knee
(Progression subcohort) and 495 African Americans and 2703 Cauca-
sians at risk for developing symptomatic radiographic KOA (Incidence
subcohort). In the current analysis, 3 distinct measures of pain severity
(KOOS [0-100], WOMAC [0-20] and NRS [0-10]) and 7 physical exam
ﬁndings were analyzed for each knee initially using bivariate methods
and, subsequently, using multiple variable linear and logistic regression
models, respectively, adjusting for body mass index, age, gender,
income, depression score, and education level.
Results: African Americans reported higher pain severity than Cauca-
sians in both knees for each assessment measure analyzed (BothTable 1
Knee pain by race/ethnicity for subjects in the Incidence and Progression cohorts
Cohort Incidence Incidence Progression Progression
Race/ethnicity African
American
Caucasian African
American
Caucasian
Right knee pain,
NRS
3.06 (2.67) 1.85 (2.16) 4.76 (4.76) 3.49 (2.59)
Right knee pain,
WOMAC
3.41 (3.71) 1.50 (2.25) 6.03 (4.37) 3.69 (3.36)
Right knee pain,
KOOS
80.1 (19.0) 89.5 (12.5) 65.4 (21.5) 76.1 (17.7)
Left knee pain, NRS 2.96 (2.88) 1.74 (2.19) 4.60 (3.08) 3.49 (2.76)
Left knee pain,
WOMAC
3.34 (4.08) 1.36 (2.35) 5.80 (4.89) 3.46 (3.62)
Left knee pain,
KOOS
80.8 (20.7) 90.6 (13.0) 67.4 (24.2) 77.7 (19.1)
Table 2
Knee exam ﬁndings by race/ethnicity for subjects in the Incidence and Progression coho
Cohort Incidence
Race/ethnicity African American
Right patellar tendon pain 106 (21.5%)
Right knee ﬂexion pain 83 (16.8%)
Right lateral jointline tender 125 (25.3%)
Right medial jointline tender 137 (27.7%)
Right knee crepitus 185 (37.5%)
Right knee patellar grind 79 (16.2%)
Left patellar tendon pain 102 (20.8%)
Left knee ﬂexion pain 96 (19.5%)
Left lateral jointline tender 116 (23.6%)
Left medial jointline tender 125 (25.4%)
Left knee crepitus 185 (37.6%)
Left knee patellar grind 83 (17.1%)subcohorts: P < 0.0001 for all comparisons) (Table 1). Furthermore,
there were signiﬁcant differences in physical examination ﬁndings
between African Americans and Caucasians for the majority of physical
examination features in both knees in both subcohorts (Table 2). After
adjustment for these differences in physical examination ﬁndings as
well as multiple confounding variables (see above), African-Americans
continued to report greater pain severity than Caucasians both in the
absence of symptomatic radiographic KOA (Incidence subcohort: P <
0.0001 for all pain outcomes) and in the presence of symptomatic
radiographic KOA (Progression subcohort: P < 0.05 for all pain
outcomes except left knee pain in the last 7 days measured by NRS).
Conclusions: These results demonstrate that African Americans report
more pain than Caucasians, even after adjusting for sociodemographic
factors, depressive symptoms and obesity, and that, regardless of the
cause, this difference cannot be explained by ﬁndings on physical exam-
ination. Further analyses should examine the potential role of coping
mechanisms, ﬁndings on magnetic resonance imaging of the knees and
access to both nonpharmacologic and pharmacologic interventions.
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P-188, ANTI-TNF-a AND OP-1: A NOVEL TRIAD IN THE PREVENTION
OF POST-TRAUMATIC OSTEOARTHRITIS
R. Olewinski, A. Hakimiyan, L. Rappoport, C. Pacione, M. Wimmer,
S. Chubinskaya. Rush Univ. Med. Ctr., Chicago, IL, USA
Purpose: This continuing study investigated the utility of individual or
combined pro-anabolic and anti-catabolic biologic interventions tar-
geting chondroprotection and cartilage repair in an ex vivo acute injury
model of post-traumatic osteoarthritis (PTOA) in human ankle cartilage.
Methods: Fifteen normal tali obtained from organ donors through the
Gift of Hope Organ and Tissue Donor Network were impacted using
a 4mm cylindrical indenter with 600N following a model previously
described. 8mm cartilage explants comprising the 4mm impacted
core and the immediately adjacent 4mm non-impacted ring were
cultured for 14 days in the presence of 5% serum and osteogenic
protein-1 (OP-1), two doses of interleukin (IL)-1 receptor antagonist
(IL-RA); tumor necrosis factor-a (TNF-a) antagonist, N-Acetyl-L-
Cysteine (NAC), two pan caspase inhibitors, P-188 surfactant, or the
combination of P-188, OP-1, and anti-TNF-a (Triad). Controls included
untreated impacted and non-impacted explants. Tissue and media
samples were collected on days 0, 2, 7, and 14 to assess cell survival
and metabolic activity. Samples were analyzed for cell viability (live/
dead assay), apoptosis (Tunel assay), matrix integrity (Safranin O
staining, Mankin score), and proteoglycan synthesis and content.
Results: A single impact to human articular cartilage resulted in cell
death/apoptosis within the impacted core, which if untreated, expanded
to the adjacent non-impacted ring. Sustainable signiﬁcant increase in cell
survival was observed under the treatment with OP-1 and more so in
Triad (24% and 43%, p<.001 respectively). These same treatments were
the most signiﬁcant in stimulating PG synthesis (5-fold and 6-fold,
p<.001 respectively). Two of the triad components (TNF-a antagonist
and P-188), when given alone did not show any signiﬁcant effect on PGs.
P-188, OP-1, and TNF-a antagonist in combination showed a better pres-
ervation of matrix integrity as evidenced by normal pattern of Safranin O
staining throughout the entire section. Mankin score was within range of
non-impacted control and was about 2-fold lower than the impactedrts
Incidence Progression Progression
Caucasian African American Caucasian
283 (10.6%) 104 (28.8%) 174 (18.0%)
285 (10.8%) 141 (39.2%) 279 (29.0%)
459 (17.2%) 129 (40.5%) 293 (30.4%)
562 (21.0%) 150 (41.6%) 298 (30.9%)
916 (34.3%) 219 (61.0%) 510 (52.9%)
218 (8.7%) 110 (31.0%) 193 (20.0%)
296 (11.0%) 114 (30.9%) 174 (18.0%)
289 (10.8%) 149 (40.5%) 293 (30.4%)
395 (14.7%) 126 (34.2%) 233 (24.1%)
591 (22.0%) 152 (41.3%) 336 (34.7%)
912 (34.0%) 223 (61.1%) 516 (53.4%)
233 (8.7%) 116 (32.2%) 210 (21.8%)
Abstracts / Osteoarthritis and Cartilage 20 (2012) S10–S53 S49controlat all timepoints (p<.001).Whengiven individually, thesebiologic
agents had less pronounced effect on the preservation of Safranin O
staining, yet remained better than other tested agents.
Conclusions: PTOA therapies will be most effective if a multi-mecha-
nistic approach is utilized to prevent chondrocyte death andmatrix loss
and to stimulate reparative responses. Combination of treatments that
target three distinct mechanisms: cell membrane protection (P-188),
inhibition of catabolism (anti-TNF-a), and stimulation of anabolic
responses (OP-1) appears to be themost promising approach to biologic
intervention of PTOA. Importantly, this Triad shows promise for rapid
translation into clinical settings since all three factors have already been
approved by the FDA for other use.
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INTRA-ARTICULAR BLOOD COAGULATION AGGRAVATES JOINT
DAMAGE AFTER A BLEED IN A CANINE IN VIVO MODEL
M.E. van Meegeren, G. Roosendaal, A.D. Barten-van Rijbroek,
S.C. Mastbergen, F.P. Lafeber. Univ. Med. Ctr. Utrecht, Utrecht, Netherlands
Purpose: Joint bleeding due to trauma, major joint surgery, or hemo-
philia leads to joint damage. However, it is unclear if there are differ-
ences between coagulating blood and anticoagulated blood with
respect to joint degeneration, especially in vivo. Therefore, we evaluated
in a canine in vivo model whether intra-articular blood exposure is
more destructive in case of coagulating blood compared to anti-
coagulated blood, and whether inﬂammation plays a role in the carti-
lage damaging process.
Methods: In 7 dogs left knees were injected with coagulating blood 4
times a week in week 1 and 4; right knees with saline. In 7 other dogs
anticoagulated, heparinized blood was injected with heparinized saline
as control. Ten weeks after the last injection cartilage matrix turnover
and synovial inﬂammation were analyzed ex vivo. To study cartilage
damage without involvement of synovial inﬂammation, healthy full
thickness human cartilage explants were exposed in vitro to coagulating
and anticoagulated blood for 4 days (n¼6). Cartilage matrix turnover
was determined at day 16.
Results: Canine knees injected with coagulating blood showed an
increase of both newly formed and total (resident) glycosaminoglycans
of 9% and 15%, respectively (p¼0.04 and p¼0.01, respectively), as well as
a decreased proteoglycan content of 6%. Injection with coagulating and
anticoagulated blood caused an increase of proteoglycan synthesis rate
of 24% and 14%, respectively (p¼0.01 and p¼0.04, respectively), as
a characteristic of (ineffective) repair activity. Intra-articular injections
with coagulating blood led to more synovial inﬂammation on macro-
scopy as well as histology (p<0.001and p¼0.01, respectively), in
contrast to knees injected with anticoagulated blood. Coagulation of
blood in vitro resulted in more cartilage damage compared to anti-
coagulated blood. This was expressed as more reduction of proteo-
glycan synthesis rate by coagulating blood compared to anticoagulated
blood (17% difference; p¼0.05), and a higher release of proteoglycans
after exposure to coagulating blood compared to anticoagulated blood
(94% difference; p¼0.01).
Conclusions: This study shows that coagulating blood causes more
long-lasting in vivo joint damage than anticoagulated blood; directly on
cartilage and via inﬂammation. In case of joint surgery prolonged
anticoagulation might limit the harmful effects of intra-articular blood.
Moreover, aspiration of blood would prevent joint damage.
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DEPLETION OF PERLECAN DOMAIN I HEPARAN SULFATE REGULATES
FIBROBLAST GROWTH FACTOR ACTIVITY IN CARTILAGE AND
PROTECTS AGAINST CARTILAGE LOSS AND OSTEOPHYTE
DEVELOPMENT IN POST-TRAUMATIC OSTEOARTHRITIS
C.C. Shu, C.B. Little, J. Melrose. Kolling Inst. of Med. Res., Sydney, Australia
Purpose: Fibroblast growth factors (FGF) -2 and -18 have been sug-
gested as potential therapeutic agents in osteoarthritis (OA). FGF-18
promotes chondrogenesis and cartilage repair in vitro and in animal
models. FGF-2 has demonstrated both chondroprotective and pro-
degradatory properties, potentailly dependent upon variable receptor
expression. Both FGF-2 and -18 signalling require heparan sulfate (HS)
as a coreceptor. Given its pericellular localisation, perlecan (HSPG2) has
been implicated as a critical agent in FGF-2/18 activities. We directly
investigated the role of perlecan domain I HS in the onset and
progression of post-traumatic OA, and whether the effects can be
attributed to altered FGF-2/18 signaling in articular cartilage.Methods:Male 10-weeks old wildtype (WT) and Hspg2 exon-3 null (in
which the domain I HS chains are ablated) mice underwent unilateral
destabilisation of the medial meniscus (DMM). Cartilage damage, sub-
chondral bone sclerosis and osteophyte development were scored 4-
and 8-weeks post-operatively. Femoral head cartilage (3 week old mice
both genotypes) were cultured  IL-1 (10ng/ml)  FGF-2 or -18 (0, 1, 10,
100ng/ml) for 4 days. Sulfated glycosaminoglycan (sGAG) released into
the media was quantiﬁed. Cartilage explant gene expression was ana-
lysed by real time PCR.
Results: There were no differences in cartilage aggrecan loss or struc-
tural damage 4 weeks post-DMM surgery between genotypes. At 8
weeks exon-3 null mice had signiﬁcantly less cartilage erosion thanWT
(Fig 1A). The increase in subchondral bone sclerosis post DMM did not
differ between genotypes, but osteophyte size was signiﬁcantly reduced
in exon-3 null mice at 8 weeks (Fig 1B).
There were no genotypic differences in either basal- or IL-1-stimulated
sGAG release from cartilage explants. FGF-2 did not alter sGAG release
IL-1 in either genotype at any dose. FGF-18 alone did not alter sGAG
release in either genotype, but signiﬁcantly attenuated IL-1-induced
sGAG loss (w35%) only in exon-3 null cartilage.
Therewerenodifferencesbetweengenotype ingeneexpression incontrol
or IL-1 cultures. FGF-2 alonewas generally “pro-catabolic”, up-regulating
Adamts4&5andMmp13mRNA inexon-3null cartilage. In thepresenceof
IL-1, FGF-2 decreased WT RNA yield and Gapdh mRNA, suggestive of the
detrimental effectof FGF-2 in injuredcartilage. FGF-18 in theabsenceof IL-
1 decreasedAdamts4 in both genotypes, andmarkedly suppressedMmp2
expression only in exon-3 null cartilage. Unlike FGF-2, FGF-18 did not
affect cell viability in either genotype in the presence of IL-1.
Figure 1. Cartilage erosion (A) and osteophyte size (B) in surgically
induced OA in WT and Hspg2 exon-3 null mice (n ¼ 17-20/group).
Conclusion: Increased mRNA expression in response to FGF-2
(Adamts4/5, Mmp13) and FGF-18 (Mmp2) in exon-3 null cartilage
conﬁrmed the importance of perlecan domain I HS, suggesting it acts by
sequestration and reduced presentation to receptors in cartilage. The in
vitro data suggests that reduced cartilage erosion in exon-3 null mice
post DMM surgerymay be associatedwith increased FGF-18 rather than
altered FGF-2 signalling in chondrocytes in the absence of perlecan
domain I HS. The mechanism behind reduced osteophyte size in exon-3
null mice is unclear but may result from altered stem cell differentia-
tion, endochondral ossiﬁcation, and/or activities of growth factors (e.g.
TGFb) implicated in osteophyte development. We suggest that the lack
of perlecan domain I HS chains negates FGF-18 sequestration, altering
signalling effects and in vivo cartilage remodeling. Controlling the
synthesis and/or turnover of chondrocyte perlecan and/or HS substi-
tution may provide a therapeutic target alone or in combination with
FGF-18 in the treatment in OA.
